Investing.com - Financial Markets Worldwide

Jin Medical International appoints Dr. James Jiayuan Tong as independent director

Published 24/06/2025, 17:54
Jin Medical International appoints Dr. James Jiayuan Tong as independent director
ZJYL
0.12%

Jin Medical (TASE:BLWV) International Ltd. (NASDAQ:ZJYL) announced the appointment of Dr. James Jiayuan Tong as an independent director and chairperson of its Nominating and Corporate Governance Committee. The company’s board of directors approved Dr. Tong’s appointment on Friday. He will also serve on the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee.

Dr. Tong, age 51, has more than twenty years of experience in finance, investment, healthcare, and academic research. Since March 2022, he has led strategic developments at ThorBay Holdings as its founder, focusing on alternative investments, pre-IPO strategy, healthcare ventures, and automation projects. From September 2019 to March 2022, Dr. Tong was a venture partner and director at Korea Investment Partners, specializing in venture investments in oncology, healthcare technology, neurological diseases, medical devices, and healthcare services.

Earlier in his career, Dr. Tong held executive roles as a venture partner and chief financial officer in both public and private companies, and has experience in investment banking and hospital management. He is experienced in overseeing financial operations, SEC compliance, and cross-border mergers and acquisitions. Dr. Tong holds two patents, has received academic awards, authored publications, and lectured at corporate and business events. He earned an M.D. from Peking University Health Science Center in 1996 and a Ph.D. in Neuroscience from Cold Spring Harbor Laboratory of Stony Brook University in 2001.

The company stated there are no family relationships or related party transactions between Dr. Tong and any director or executive officer of Jin Medical International that require disclosure.

This information is based on a press release statement filed with the Securities and Exchange Commission.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.